Fifth Circuit Upholds FTC Finding That Generic Drug Maker Entered into Illegal “Pay-for-Delay” Deal
- April 16, 2021
The Fifth Circuit upheld April 13 a Federal Trade Commission ruling that Impax Laboratories, LLC entered into in an illegal “pay-for-delay,” or “reverse payment,” settlement to block market entry of a lower-cost generic version of Endo Pharmaceutical Inc.’s extended-release opioid, Opana ER.
ARTICLE TAGS
You must be logged in to access this content.